Another ADC biotech reels in big bucks as Mark Alles’ TORL nabs $158M
Mark Alles has quickly put together a megaround for his latest venture, and it’s for the most sought-after pocket of oncology R&D: antibody-drug conjugates. The former Celgene CEO became chief executive of TORL BioTherapeutics three months ago, and on Wednesday the company unveiled a $158 million Series B-2. The five-year-old